Zai Lab bombs Phase IIa trial in atopic dermatitis, junks the program to shift resources to the pipeline

Nasdaq darling and Shanghai hotshot Zai Lab is ditching one of its late-stage drug programs after bombing a Phase IIa trial. The company said Friday that its topical product ZL-3101 (also called Fugan) did not clear up eczema.